Production (Stage)
Esperion Therapeutics, Inc.
ESPR
$1.17
-$0.03-2.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -89.77% | 27.79% | 52.32% | -201.48% | 208.30% |
| Total Depreciation and Amortization | -3.70% | 3.85% | 160.00% | -- | -- |
| Total Amortization of Deferred Charges | 306.40% | -61.52% | 1.13% | 1.14% | 1.39% |
| Total Other Non-Cash Items | -32.12% | 21.62% | -89.63% | 318.20% | -4.86% |
| Change in Net Operating Assets | 156.45% | -71.56% | -148.45% | 77.07% | -651.28% |
| Cash from Operations | 35.26% | 1.06% | -390.28% | -113.39% | 245.26% |
| Capital Expenditure | -- | 100.00% | -116.88% | -5.48% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -116.88% | -5.48% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -94.15% | -90.59% | 965.85% |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -105.16% | 1,610.54% | -103.16% | 5,323.87% | -27.42% |
| Cash from Financing | -121.43% | 484.78% | 69.71% | -133.14% | 1,926.53% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68,572.73% | 100.10% | -19.52% | -125.84% | 543.03% |